Stock Events

Stock Events

Theriva Biologics 

$0.2530
69
+$0.00+1.2% Friday 20:00
-$0.00-0.28%Friday 23:30After hours

Statistics

Day High
0.2529
Day Low
0.2489
52W High
0.84
52W Low
0.18
Volume
8,702
Avg. Volume
-
Mkt Cap
11.61M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jan 8
$1.19
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

17NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-7.22
-2.8
1.61
6.03
Expected EPS
-0.065
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-25.25MNet Income

Analyst Ratings

1.00Average Price Target
The highest estimate is 1.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TOVX. It's not an investment recommendation.
Apple
7
AAPL
Microsoft
7
MSFT
Realty Income
6
O
NVIDIA
6
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap55.09B
Moderna is involved in mRNA-based therapies, potentially competing in the innovative treatment space similar to Theriva Biologics' focus on novel biologic treatments.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech, like Theriva, is engaged in developing novel therapies, including mRNA-based vaccines and treatments that could overlap with Theriva's therapeutic areas.
Novavax
NVAX
Mkt Cap1.53B
Novavax competes in the development of vaccines, including those for infectious diseases, which may intersect with Theriva Biologics' focus areas.
Pfizer
PFE
Mkt Cap159.36B
Pfizer develops and markets drugs and vaccines, including in areas that could compete with Theriva's biologic treatments.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences focuses on antiviral drugs that could compete with Theriva Biologics in the infectious disease treatment market.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals specializes in monoclonal antibodies, a type of biologic treatment that could directly compete with Theriva's offerings.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals engages in creating novel therapies for treating cystic fibrosis and other serious diseases, potentially competing with Theriva's innovative treatments.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including biologic treatments, which could compete with Theriva Biologics in various therapeutic areas.
Biogen
BIIB
Mkt Cap32.28B
Biogen specializes in neurological diseases and could compete with Theriva Biologics in the development of biologic treatments for these conditions.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie works on biopharmaceuticals, including immunology and oncology, areas that may overlap with Theriva Biologics' research and development focus.

About

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
Show more...
CEO
Steven A. Shallcross
Employees
16
Country
United States
ISIN
US87164U5083
WKN
000A40MGC

Listings

STU
DE
SFY0.STU
MU
DE
SFY0.MU
F
DE
SFY0.F
XASE
US
TOVX

0 Comments

Share your thoughts

FAQ

What is Theriva Biologics stock price today?▼
The current price of TOVX is $0.25 USD — it has increased by +1.2% in the past 24 hours. Watch Theriva Biologics stock price performance more closely on the chart.
What is Theriva Biologics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XASE exchange Theriva Biologics stocks are traded under the ticker TOVX.
Is Theriva Biologics stock price growing?▼
TOVX stock has risen by +1.2% compared to the previous week, the month change is a +10% rise, over the last year Theriva Biologics has showed a -36.75% decrease.
What is Theriva Biologics market cap?▼
Today Theriva Biologics has the market capitalization of 11.61M
When is the next Theriva Biologics earnings date?▼
Theriva Biologics is going to release the next earnings report on November 17, 2026.
What were Theriva Biologics earnings last quarter?▼
TOVX earnings for the last quarter are -0.07 USD per share, whereas the estimation was -0.06 USD resulting in a -27.27% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Theriva Biologics revenue for the last year?▼
Theriva Biologics revenue for the last year amounts to 0 USD.
What is Theriva Biologics net income for the last year?▼
TOVX net income for the last year is -25.25M USD.
Does Theriva Biologics pay dividends?▼
Yes, TOVX dividends are paid annual. The last dividend per share was 1.19 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Theriva Biologics have?▼
As of September 05, 2026, the company has 16 employees.
In which sector is Theriva Biologics located?▼
Theriva Biologics operates in the Health & Wellness sector.
When did Theriva Biologics complete a stock split?▼
The last stock split for Theriva Biologics was on August 26, 2024 with a ratio of 1:25.
Where is Theriva Biologics headquartered?▼
Theriva Biologics is headquartered in ROCKVILLE, United States.